RxDoctor Payments Data

Adam Sise, MD

Ophthalmology · Portland, MENPI 1891010997

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Alcon at 24.7% of the total. Reporting peaked in 2022 at $338 and has fallen 85.0% since, to $51 in 2025.

$1,073in general payments, 2019–2025

Across 23 payments — averaging $46.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$265
  • Johnson & Johnson Surgical Vision, Inc.$193
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$167
  • Beaver-visitec International, Inc.$129
  • Mallinckrodt Hospital Products Inc.$97
  • Glaukos Corporation$49
  • plus $174 from 6 others

What the payments were for

  • Food & beverage$1,05398%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,073 in reported general payments places this provider in the 70th percentile of 74 ophthalmology providers in Maine.

See all ophthalmology providers in Maine

Medicare billing

Part B allowed, 2024
$280,929
Medicare patients
410
Services billed
5,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate995$38,706
RestasisCyclosporine21$32,759
Ketorolac Tromethamine684$17,260
Fluorometholone84$6,687
ValacyclovirValacyclovir Hcl98$5,063
Loteprednol Etabonate19$2,686
Brimonidine Tartrate51$1,016
Dexamethasone Sodium Phosphate20$979
Famciclovir17$907
Ofloxacin67$869
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim127$585
Latanoprost38$570
MoxifloxacinMoxifloxacin Hcl20$526
Acyclovir29$409
Tobramycin-DexamethasoneTobramycin/Dexamethasone12$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$43$32,75921 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$167$2,68619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 74 ophthalmology providers in Maine.

Other ophthalmology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →